FSD Pharma

HomeFSD Pharma

FSD.CN

Recent Headlines

InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-06-23
FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA
Source: FSD Pharma Published on 2020-06-22
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
Source: FSD Pharma Published on 2020-06-09
HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients
Source: FSD Pharma Published on 2020-06-09
FSD Pharma Inc. Announces C$10.125 Million Private Placement
Source: FSD Pharma Published on 2020-06-04
Covid Report: Small Biotech Triples On Plans To Test A Coronavirus Drug
Source: FSD Pharma Published on 2020-06-03
/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions/
Source: FSD Pharma Published on 2020-06-03
IIROC Trading Halt - HUGE
Source: FSD Pharma Published on 2020-06-03
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
Source: FSD Pharma Published on 2020-06-03
FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
Source: FSD Pharma Published on 2020-06-03
FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc.
Source: FSD Pharma Published on 2020-05-21
FSD Pharma Monetizes Non-Core Asset With Sale of Partial Equity Stake in Pharmadrug Inc.
Source: FSD Pharma Published on 2020-05-21
FSD Pharma Reports First Quarter 2020 Financial Results
Source: FSD Pharma Published on 2020-05-14
FSD Pharma Reports First Quarter 2020 Financial Results
Source: FSD Pharma Published on 2020-05-14
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario
Source: FSD Pharma Published on 2020-03-23
InvestmentPitch Media Video Discusses FSD Pharma's Initiation of Phase 1 In-Human Safety & Tolerability Study of Dosing Ultra Micro-PEA for Targeting CB2 Receptors at Alfred Hospital in Australia - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-03-10
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
Source: FSD Pharma Published on 2020-03-09
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
Source: FSD Pharma Published on 2020-03-09
FSD Pharma Inc., Worldwide License of Natural Fatty Acid, CEO Clip Video
Source: FSD Pharma Published on 2020-03-06
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020
Source: FSD Pharma Published on 2020-03-04
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020
Source: FSD Pharma Published on 2020-03-04
InvestmentPitch Media Video Discusses FSD Pharma's Sale of its 12% Interest in Cannara Biotech Generating 670% Return and $7.7 million in Proceeds - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-02-24
FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech
Source: FSD Pharma Published on 2020-02-20
FSD Pharma CEO, Dr. Raza Bokhari, Discusses 2020 Goals with The Stock Day Podcast
Source: FSD Pharma Published on 2020-02-11
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
Source: FSD Pharma Published on 2020-02-05
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
Source: FSD Pharma Published on 2020-02-05
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
Source: FSD Pharma Published on 2020-02-04
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
Source: FSD Pharma Published on 2020-02-04
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
Source: FSD Pharma Published on 2020-01-22
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
Source: FSD Pharma Published on 2020-01-22
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
Source: FSD Pharma Published on 2020-01-17
InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-01-10
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’
Source: FSD Pharma Published on 2020-01-09
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'
Source: FSD Pharma Published on 2020-01-09
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020
Source: FSD Pharma Published on 2020-01-06
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020
Source: FSD Pharma Published on 2020-01-06
FSD Pharma Strengthens Management Team
Source: FSD Pharma Published on 2020-01-02
FSD Pharma Strengthens Management Team
Source: FSD Pharma Published on 2020-01-02
InvestmentPitch Media Video Discusses FSD Pharma's Approval of Listing Application for Nasdaq Capital Market with trading Anticipated to Begin Shortly - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2019-12-17
IIROC Trade Resumption - HUGE
Source: FSD Pharma Published on 2019-12-16
FSD Pharma Receives Approval to List its Shares on Nasdaq
Source: FSD Pharma Published on 2019-12-16
FSD Pharma Receives Approval to List Its Shares on Nasdaq
Source: FSD Pharma Published on 2019-12-16
IIROC Trading Halt - HUGE
Source: FSD Pharma Published on 2019-12-13
FSD Pharma to Present at Investor Summit on December 17
Source: FSD Pharma Published on 2019-12-13
HUGE.CN: FSD Pharma to Initiate a Phase 1 clinical trial of PP-101 micro-PEA during 1Q 2020
Source: FSD Pharma Published on 2019-12-13
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11
Source: FSD Pharma Published on 2019-12-05
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11
Source: FSD Pharma Published on 2019-12-05
FSD Pharma Reports Third Quarter 2019 Financial Results
Source: FSD Pharma Published on 2019-11-29
FSD Pharma Reports Third Quarter 2019 Financial Results
Source: FSD Pharma Published on 2019-11-29
Canadian Securities Exchange Attracts First Israeli Company Listings
Source: FSD Pharma Published on 2019-11-05

Login
Register